Attached files

file filename
EX-32.2 - EXHIBIT 32.2 - EYEGATE PHARMACEUTICALS INCv459809_exh32x2.htm
EX-31.2 - EXHIBIT 31.2 - EYEGATE PHARMACEUTICALS INCv459809_exh31x2.htm
EX-31.1 - EXHIBIT 31.1 - EYEGATE PHARMACEUTICALS INCv459809_exh31x1.htm
EX-23.1 - EXHIBIT 23.1 - EYEGATE PHARMACEUTICALS INCv459809_exh23x1.htm
EX-21.1 - EXHIBIT 21.1 - EYEGATE PHARMACEUTICALS INCv459809_exh21x1.htm
EX-10.19 - EXHIBIT 10.19 - EYEGATE PHARMACEUTICALS INCv459809_exh10x19.htm
10-K - 10-K - EYEGATE PHARMACEUTICALS INCv459809_10k.htm

Exhibit 32.1

CERTIFICATION OF PERIODIC FINANCIAL REPORT
PURSUANT TO 18 U.S.C. SECTION 1350

The undersigned officer of EyeGate Pharmaceuticals, Inc. (the “Company”) hereby certifies to his knowledge that the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 (the “Report”) to which this certification is being furnished as an exhibit, as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. This certification is provided solely pursuant to 18 U.S.C. Section 1350 and Item 601(b)(32) of Regulation S-K (“Item 601(b)(32)”) promulgated under the Securities Act of 1933, as amended (the “Securities Act”), and the Exchange Act. In accordance with clause (ii) of Item 601(b)(32), this certification (A) shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and (B) shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

Date: February 23, 2017

/s/ Stephen From

Stephen From
President and Chief Executive Officer
(Principal executive officer)